173 related articles for article (PubMed ID: 7694550)
1. Transgenic models of skin diseases.
Rothnagel JA; Greenhalgh DA; Wang XJ; Sellheyer K; Bickenbach JR; Dominey AM; Roop DR
Arch Dermatol; 1993 Nov; 129(11):1430-6. PubMed ID: 7694550
[TBL] [Abstract][Full Text] [Related]
2. A transgenic mouse model that recapitulates the clinical features of both neonatal and adult forms of the skin disease epidermolytic hyperkeratosis.
Bickenbach JR; Longley MA; Bundman DS; Dominey AM; Bowden PE; Rothnagel JA; Roop DR
Differentiation; 1996 Dec; 61(2):129-39. PubMed ID: 8983179
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha.
Greenhalgh DA; Wang XJ; Donehower LA; Roop DR
Cancer Res; 1996 Oct; 56(19):4413-23. PubMed ID: 8813135
[TBL] [Abstract][Full Text] [Related]
4. Transgenic mice provide genetic evidence that transforming growth factor alpha promotes skin tumorigenesis via H-ras-dependent and H-ras-independent pathways.
Jhappan C; Takayama H; Dickson RB; Merlino G
Cell Growth Differ; 1994 Apr; 5(4):385-94. PubMed ID: 8043512
[TBL] [Abstract][Full Text] [Related]
5. Transgenic coexpression of v-Ha-ras and transforming growth factor alpha increases epidermal hyperproliferation and tumorigenesis and predisposes to malignant conversion via endogenous c-Ha-ras activation.
Wang XJ; Greenhalgh DA; Roop DR
Mol Carcinog; 2000 Mar; 27(3):200-9. PubMed ID: 10708482
[TBL] [Abstract][Full Text] [Related]
6. Cooperation between v-fos and v-rasHA induces autonomous papillomas in transgenic epidermis but not malignant conversion.
Greenhalgh DA; Quintanilla MI; Orengo CC; Barber JL; Eckhardt JN; Rothnagel JA; Roop DR
Cancer Res; 1993 Nov; 53(21):5071-5. PubMed ID: 7693330
[TBL] [Abstract][Full Text] [Related]
7. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development.
Larcher F; Murillas R; Bolontrade M; Conti CJ; Jorcano JL
Oncogene; 1998 Jul; 17(3):303-11. PubMed ID: 9690512
[TBL] [Abstract][Full Text] [Related]
8. Targeted overexpression of transforming growth factor alpha in the epidermis of transgenic mice elicits hyperplasia, hyperkeratosis, and spontaneous, squamous papillomas.
Dominey AM; Wang XJ; King LE; Nanney LB; Gagne TA; Sellheyer K; Bundman DS; Longley MA; Rothnagel JA; Greenhalgh DA
Cell Growth Differ; 1993 Dec; 4(12):1071-82. PubMed ID: 8117621
[TBL] [Abstract][Full Text] [Related]
9. Lessons from keratin transgenic and knockout mice.
Magin TM
Subcell Biochem; 1998; 31():141-72. PubMed ID: 9932492
[No Abstract] [Full Text] [Related]
10. 12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mouse epidermis coexpressing transforming growth factor-alpha and v-fos: acceleration of autonomous papilloma formation and malignant conversion via c-Ha-ras activation.
Wang XJ; Liefer KM; Greenhalgh DA; Roop DR
Mol Carcinog; 1999 Dec; 26(4):305-11. PubMed ID: 10569807
[TBL] [Abstract][Full Text] [Related]
11. Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice.
Arbeit JM; Riley RR; Huey B; Porter C; Kelloff G; Lubet R; Ward JM; Pinkel D
Cancer Res; 1999 Aug; 59(15):3610-20. PubMed ID: 10446971
[TBL] [Abstract][Full Text] [Related]
12. Keratins and skin disorders.
Lane EB; McLean WH
J Pathol; 2004 Nov; 204(4):355-66. PubMed ID: 15495218
[TBL] [Abstract][Full Text] [Related]
13. Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development.
Pierce AM; Fisher SM; Conti CJ; Johnson DG
Oncogene; 1998 Mar; 16(10):1267-76. PubMed ID: 9546428
[TBL] [Abstract][Full Text] [Related]
14. Genetic approaches to understanding the keratinopathies.
Bale SJ; DiGiovanna JJ
Adv Dermatol; 1997; 12():99-113; discussion 114. PubMed ID: 8973737
[TBL] [Abstract][Full Text] [Related]
15. Human keratin-1.bcl-2 transgenic mice aberrantly express keratin 6, exhibit reduced sensitivity to keratinocyte cell death induction, and are susceptible to skin tumor formation.
Rodríguez-Villanueva J; Greenhalgh D; Wang XJ; Bundman D; Cho S; Delehedde M; Roop D; McDonnell TJ
Oncogene; 1998 Feb; 16(7):853-63. PubMed ID: 9484776
[TBL] [Abstract][Full Text] [Related]
16. Targeted expression of activated erbB-2 to the epidermis of transgenic mice elicits striking developmental abnormalities in the epidermis and hair follicles.
Xie W; Wu X; Chow LT; Chin E; Paterson AJ; Kudlow JE
Cell Growth Differ; 1998 Apr; 9(4):313-25. PubMed ID: 9563851
[TBL] [Abstract][Full Text] [Related]
17. Hyperplasia, hyperkeratosis and benign tumor production in transgenic mice by a targeted v-fos oncogene suggest a role for fos in epidermal differentiation and neoplasia.
Greenhalgh DA; Rothnagel JA; Wang XJ; Quintanilla MI; Orengo CC; Gagne TA; Bundman DS; Longley MA; Fisher C; Roop DR
Oncogene; 1993 Aug; 8(8):2145-57. PubMed ID: 7687760
[TBL] [Abstract][Full Text] [Related]
18. Keratin transgenic and knockout mice: functional analysis and validation of disease-causing mutations.
Vijayaraj P; Söhl G; Magin TM
Methods Mol Biol; 2007; 360():203-51. PubMed ID: 17172732
[TBL] [Abstract][Full Text] [Related]
19. Inducible mouse models for inherited skin diseases: implications for skin gene therapy.
Arin MJ; Roop DR
Cells Tissues Organs; 2004; 177(3):160-8. PubMed ID: 15388990
[TBL] [Abstract][Full Text] [Related]
20. Mild recessive epidermolytic hyperkeratosis associated with a novel keratin 10 donor splice-site mutation in a family of Norfolk terrier dogs.
Credille KM; Barnhart KF; Minor JS; Dunstan RW
Br J Dermatol; 2005 Jul; 153(1):51-8. PubMed ID: 16029326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
